SAS Banner
SAS Mobile Banner

Langer, Jerome A

Jerome A. Langer
Associate Professor
Robert Wood Johnson Medical School
Department of Pharmacology
Research Tower, Rm 729
Piscataway, NJ 08854
(732) 235-5224
This email address is being protected from spambots. You need JavaScript enabled to view it.

Structure and function of interferons and interferon receptors; development of Type I IFN antagonists; role of IFNs in autoimmune diseases such as lupus

We are currently interested in 2 related areas: (1) understanding the differential action of the 17 human Type I interferons (IFNs); (2) the role of IFNs in systemic lupus erythematosus ("lupus") and autoimmunity, including the development of IFN analogues that act as competitive antagonists to endogenous IFNs.

The 13 IFN-alphas, and IFN-beta, IFN-omega, IFN-kappa and IFN-epsilon produce differential activation of cells and, in some cases, different physiological and clinical efficacies. However, they all act through a common heterodimeric cell-surface receptor, IFNAR. Recent evidence suggests that, to a first approximation, some of the differential effects come from different interactions of the IFNs with the low-affinity receptor subunit IFNAR-1. Dr. Langer's group previously identified regions of IFNAR-1 that are involved in binding IFNs. More recently, his group has used mutagenesis to help identify critical regions of Type I IFNs that interact with IFNAR-1. Continued mutagenesis and structure/function studies will help us understand the degree to which these interactions modulate IFN responses.

Our work on understanding the IFN/IFNAR-1 interaction is critical to our efforts to develop novel competitive antagonists for Type I IFNs. There is good evidence that the aberrant production of Type I interferons in people with lupus helps drive the progression of this disease. Type I IFNs may also be involved in the pathogenesis of several other autoimmune diseases, and in other clinical situations. Dr. Langer’s group is trying to genetically engineer and produce Type I interferon variants that can block the receptor binding and activity of endogenous Type I interferons, i.e., they will act as competitive antagonists. Antagonists are being designed and tested both for use in humans and for animal models.



Contact Us

Division of Life Sciences Graduate Program Office
Rutgers, The State University of New Jersey
Nelson Lab-604 Allison Rd
Piscataway, NJ 08854
Phone: 848.445.9517